Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.

@article{Lewitt1989ControlledreleaseC,
  title={Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.},
  author={Peter A Lewitt and Marilyn V. Nelson and Richard C. Berchou and Matthew Peter Galloway and Nirmala Kesaree and D Kareti and P Schlick},
  journal={Neurology},
  year={1989},
  volume={39 11 Suppl 2},
  pages={45-53; discussion 59}
}
Several controlled-release carbidopa/levodopa preparations have been formulated to achieve a more stable and extended antiparkinsonian action. The most effective is Sinemet CR (Sinemet CR4), with an erodible polymer matrix that retards release of levodopa. In 19 parkinsonians with prominent dose-by-dose fluctuations, double-blind crossover trials comparing 8-week regimens of standard carbidopa/levodopa (25/100) to Sinemet CR (50/200) showed comparable clinical outcomes, with mean daily dosing… CONTINUE READING

From This Paper

Topics from this paper.
16 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Similar Papers

Loading similar papers…